Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
There is an increase in false susceptible results for enterobacteriaceae acinetobacter species and pseudomonas aeruginosa isolates on rapid neg bp combo type 3 (b1017-117)and rapid neg urine combo type 1 (b1017-167) panels as compared to frozen reference panels with the four key drugs evaluated (aztreonam cefotaxime ceftazidime and ceftriaxone). the false susceptible results could lead to the potential treatment of patients with an ineffective antibiotic.